List of Excipients in Branded Drug ORSERDU

ORSERDU Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Orserdu (elacestrant) is an oral, film-coated tablet for estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations after progression on at least one line of endocrine therapy. Its commercial formulation is relatively conventional: immediate-release tablets in 86 mg and 345 mg strengths, supplied by Menarini Group and Radius Health. The main excipient opportunities are generic formulation development, food-effect control, dose-flexibility products, differentiated patient-friendly dosage forms, and manufacturing cost reduction rather than discovery of a new active pharmaceutical ingredient.

The product’s near-term competitive risk is likely to arise through abbreviated new drug applications, 505(b)(2) products, and formulation workarounds. Biosimilar competition does not apply because elacestrant is a chemically synthesized small molecule, not a biologic.

What is Orserdu and how is it formulated?

Orserdu contains elacestrant hydrobromide, an orally active selective estrogen receptor degrader. The FDA approved Orserdu on January 27, 2023, under the NDA pathway for adults with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations after endocrine therapy progression. The recommended dose is 345 mg once daily with food. The 86 mg tablet supports dose reduction and dose-management requirements in the prescribing information (U.S. Food and Drug Administration [FDA], 2023a).

Product attribute	Publicly reported information
Active ingredient	Elacestrant hydrobromide
Brand	Orserdu
Applicant	Menarini Group and Radius Health
FDA approval	January 27, 2023
Dosage form	Oral film-coated tablet
Marketed strengths	86 mg and 345 mg
Standard dose	345 mg once daily with food
Dose-reduction strength	86 mg
Therapeutic category	Endocrine therapy, estrogen receptor degradation
FDA pathway	New drug application
Biosimilar pathway	Not applicable
Likely generic pathway	ANDA, subject to patent and exclusivity restrictions

The FDA label identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate. The tablets also use a film-coating system containing standard coating polymers, plasticizers, pigments, and opacifying agents. Exact supplier grades and manufacturing parameters are not generally disclosed in the public label and may remain valuable know-how (FDA, 2023a).

What excipients are used in Orserdu tablets?

The public formulation indicates a conventional direct-compression or wet-granulation platform rather than a lipid-based, amorphous solid-dispersion, osmotic, or modified-release system.

Core excipients

The principal excipient functions are:

Excipient	Likely functional role
Lactose monohydrate	Diluent and tablet-mass builder
Microcrystalline cellulose	Filler, dry binder, and compression aid
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Film-coating excipients	Appearance, swallowability, protection, identification, and mechanical durability

This composition creates several generic-development opportunities. The active can potentially be paired with alternative diluents, disintegrants, lubricants, or coating systems if the resulting product meets dissolution, stability, bioequivalence, impurity, and manufacturing requirements.

The most commercially important formulation issue is not excipient novelty. It is the relationship between tablet composition, elacestrant exposure, and administration with food.

Why does Orserdu require administration with food?

The label directs patients to take Orserdu with food at approximately the same time each day. Food administration is commercially relevant because it creates a formulation-development target. A generic manufacturer may seek to reproduce the reference product’s fed-state exposure, while a 505(b)(2) sponsor could pursue a formulation that reduces sensitivity to meal composition or permits more convenient dosing.

Elacestrant exposure is affected by food, and the label also instructs patients to avoid grapefruit and grapefruit juice because of potential drug-interaction effects. These requirements create three possible development paths:

1. Reference-matched immediate-release tablet. This is the most direct ANDA strategy. The developer would match the reference product’s dissolution profile and demonstrate bioequivalence under the FDA-required conditions.

2. Food-effect mitigation. A formulation using particle-size control, wetting agents, a solid-dispersion approach, or a lipid-compatible delivery system could seek to reduce variability caused by meal composition. Such a product would likely require a 505(b)(2) route if it materially changes administration conditions or clinical performance.

3. Patient-convenience positioning. A tablet that supports administration with a broader range of meals, or potentially without food, would have commercial value for oncology patients who experience nausea, reduced appetite, or irregular meal schedules. The regulatory burden would be higher because the sponsor would need clinical pharmacology evidence supporting the revised administration instruction.

A formulation change that improves food independence could be more commercially meaningful than a simple excipient substitution. The sponsor would need to show that altered exposure does not increase toxicity, particularly for adverse reactions associated with elacestrant’s pharmacologic activity.

What formulation patents could protect Orserdu?

Formulation protection could cover more than the excipient list. Relevant claim categories include:

• specific crystalline or polymorphic forms of elacestrant or its hydrobromide salt;
• particle-size distributions;
• tablet compositions containing defined active-to-excipient ratios;
• dissolution profiles;
• processes for granulation, drying, compression, or coating;
• formulations that control food-related exposure;
• methods of reducing gastrointestinal adverse events;
• dosage regimens using the 86 mg and 345 mg strengths;
• combination use with CDK4/6 inhibitors, PI3K-pathway agents, or other endocrine therapies;
• treatment of ESR1-mutated breast cancer after specified prior therapy.

A formulation patent can create a barrier even when the active-ingredient patent is vulnerable. The practical strength of such patents depends on claim breadth, enablement, written-description support, prosecution history, and whether a generic can use a different excipient system while achieving the same clinical and dissolution requirements.

The public FDA label does not disclose the complete patent prosecution record or manufacturing know-how. Orange Book patent status must be assessed against the current FDA listing and the relevant United States Patent and Trademark Office records. Patent numbers, claims, and expiration dates should not be inferred from the approval date alone.

When does Orserdu lose FDA exclusivity?

Orserdu received five-year new chemical entity exclusivity because elacestrant was approved as a new active moiety. The five-year period runs from the FDA approval date of January 27, 2023. Subject to statutory exceptions and patent conditions, an ANDA generally cannot be approved before January 27, 2028. A Paragraph IV applicant could file earlier, but the filing does not itself permit commercial launch before applicable exclusivity and patent barriers expire (FDA, 2023b).

Milestone	Date or status
FDA approval	January 27, 2023
Five-year NCE exclusivity	Expected to run through January 27, 2028
Earliest routine ANDA approval window	January 27, 2028, subject to listed patents
Pediatric exclusivity	Not assumed without an FDA-recognized grant
Orphan exclusivity	Not identified as the primary approval protection
Biosimilar exclusivity	Not applicable

Patent expiration may extend beyond regulatory exclusivity. For a commercial launch analysis, the critical date is the later of applicable FDA exclusivity restrictions and enforceable patent barriers, subject to Paragraph IV litigation, settlement terms, patent-term adjustment, patent-term extension, and claim scope.

What Paragraph IV challenges and generic entry risks exist for Orserdu?

The principal generic entry route is an ANDA containing a Paragraph IV certification against any listed patent that the applicant believes is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger litigation by the NDA holder or patent owner. The filing of a timely patent-infringement action can create a 30-month stay of FDA approval, subject to statutory limitations (FDA, 2023b).

Generic entry risks fall into four categories:

Active-ingredient and salt patents

Claims directed to elacestrant, its hydrobromide salt, crystalline forms, or synthetic processes can block a straightforward copy. Process patents are less durable if the generic can manufacture the same active using a non-infringing route.

Formulation patents

A generic applicant may avoid a formulation patent by changing the diluent, disintegrant, lubricant, coating, or manufacturing process. That workaround is viable only if the resulting product remains bioequivalent and satisfies dissolution and stability requirements.

Method-of-use patents

Orserdu’s approved use is limited to a genetically defined and treatment-experienced breast-cancer population. Method-of-use patents may be relevant if they claim ESR1-mutated disease, a treatment sequence, or a particular endocrine combination. Generic applicants can seek a section viii label carve-out for patented uses, although the commercial value of the product may be reduced if the carve-out removes the principal approved indication.

Manufacturing and supply-chain barriers

Elacestrant production requires control of salt formation, impurity profile, polymorphic form, particle properties, and residual solvents. These are not necessarily visible in the final tablet but can affect bioequivalence and stability. Supplier qualification for specialty excipients, coating pigments, and active-ingredient intermediates may also influence launch timing.

How strong is the Orserdu patent estate?

The estate should be assessed as a layered pharmaceutical portfolio rather than a single blocking right.

Layer	Strategic value	Generic vulnerability
Active compound	High if claims remain broad and unexpired	Potential validity and prior-art challenges
Hydrobromide salt or solid form	High for controlling the commercial API	Workarounds may be possible with alternative forms
Tablet formulation	Moderate to high	Excipients and process may be substituted
Food-effect management	Potentially high	Requires credible pharmacokinetic and clinical support
Manufacturing process	Moderate	Non-infringing synthesis may be available
Method of use	High in the target population	Label carve-outs may reduce practical blocking power
Combination therapy	Potentially valuable for lifecycle management	Depends on clinical adoption and claim scope

The strongest commercial protection would combine a durable active or solid-form patent with a formulation patent tied to a clinically meaningful benefit, such as improved food independence, reduced variability, or lower toxicity. A narrow excipient-only claim is less likely to block all generic approaches.

What commercial opportunities exist in Orserdu excipients?

Generic reference-product development

The largest opportunity is development of an ANDA-ready immediate-release tablet. Manufacturers can compete on:

• lower-cost excipient sourcing;
• high-throughput compression;
• reduced coating time;
• improved tablet robustness;
• tighter content-uniformity controls;
• packaging that improves moisture protection;
• scalable production of both 86 mg and 345 mg strengths.

A formulation must match the reference product’s in-vitro and in-vivo performance. Cost savings from replacing a commodity excipient are likely to be modest unless the change improves process yield or eliminates a manufacturing bottleneck.

505(b)(2) food-effect product

A differentiated product that reduces dependence on food could command a premium if supported by pharmacokinetic and adherence data. Candidate technologies include:

• micronized or nanocrystalline elacestrant;
• wetting-agent systems;
• amorphous solid dispersions;
• self-emulsifying drug-delivery systems;
• lipid-based tablets or capsules;
• polymeric precipitation-inhibition systems;
• multiparticulate dosage forms.

These approaches may create new intellectual property, but they also introduce scale-up, stability, content-uniformity, and regulatory risks. For a chronic oncology product, the commercial case must show a clinically relevant benefit rather than a laboratory dissolution improvement alone.

Dose-flexibility products

The 86 mg strength provides a base for alternative dose-management products. Opportunities include lower-dose tablets, scored tablets where technically appropriate, mini-tablets, or a multiparticulate presentation. The product’s labeling, however, may limit the commercial value of a new strength unless the sponsor obtains supporting regulatory approval.

Pediatric and swallowing-focused formats

Breast cancer incidence in pediatric populations is not a principal commercial driver, but oncology patients with dysphagia, nausea, or treatment-related fatigue may benefit from smaller tablets or alternative oral formats. Orally disintegrating tablets, sprinkle formulations, and capsules could be evaluated under a 505(b)(2) strategy. Palatability is less important than dose accuracy, rapid disintegration, chemical stability, and compatibility with food.

Excipient supplier partnerships

Excipient suppliers can target:

• directly compressible lactose and cellulose grades;
• high-efficiency crospovidone;
• low-peroxide polymers;
• magnesium-stearate alternatives;
• film coatings with improved opacity and abrasion resistance;
• continuous-manufacturing systems;
• ready-to-use coating premixes.

The strongest value proposition is process performance. A supplier that reduces tablet defects, improves dissolution consistency, or shortens coating cycles may gain share even when the excipient itself is not patent-protected.

How does Orserdu compare with competing endocrine therapies?

Orserdu competes with fulvestrant, aromatase inhibitors, tamoxifen, and investigational oral selective estrogen receptor degraders. Its distinction is oral administration and selection for ESR1-mutated, endocrine-resistant disease. Fulvestrant is injectable, while aromatase inhibitors are oral but do not target the estrogen receptor through the same degradation mechanism.

Attribute	Orserdu	Fulvestrant	Aromatase inhibitors
Administration	Oral tablet	Intramuscular injection	Oral tablet
Target	Estrogen receptor degradation	Estrogen receptor degradation	Estrogen synthesis inhibition
ESR1-mutated population	Approved use	Used clinically, but different regulatory positioning	Reduced activity may occur with resistance
Food requirement	Taken with food	Not applicable	Product-specific
Excipient opportunity	High for tablet and food-effect work	Low for oral excipients	Established generic competition
Biosimilar risk	None	None as a small molecule	None as a small molecule
Main competitive issue	Oral endocrine-resistance treatment	Injection burden and clinical sequencing	Low-cost generic availability

Orserdu’s food requirement is a disadvantage relative to an oral product that can be taken independently of meals. That weakness creates a clear formulation-development target.

What is the FDA and Orange Book status of Orserdu?

Orserdu is an FDA-approved prescription drug listed as an oral tablet under an NDA. Its regulatory protection includes NCE exclusivity beginning on January 27, 2023. The product is not eligible for biosimilar substitution because it is not a biologic.

Orange Book analysis should distinguish:

• FDA exclusivity from patent protection;
• active-ingredient patents from method-of-use patents;
• patents that block approval from patents that only affect specific labeled uses;
• listed patents from patents that remain enforceable after litigation or settlement;
• an ANDA filing date from an actual commercial launch date.

The commercial launch window cannot be determined from NCE exclusivity alone. Patent certification, litigation, settlement provisions, pediatric exclusivity, and any patent-term adjustment can materially alter entry timing.

What licensing and partnering opportunities exist?

Menarini’s control of Orserdu creates partnering opportunities in territories where it has limited oncology infrastructure. The most logical transactions involve:

• regional commercialization rights;
• co-promotion with breast-cancer specialists;
• companion-diagnostic distribution for ESR1 mutation testing;
• contract manufacturing of tablets;
• development of food-effect or adherence-improving formulations;
• lifecycle products for earlier-line endocrine therapy;
• combination regimens with targeted agents.

The commercial value of a formulation license depends on whether the formulation obtains a separate regulatory label and creates enforceable intellectual property. A formulation that only reduces manufacturing cost may be more suitable for a supply agreement than a royalty-bearing license.

What revenue exposure could generic entry create?

Orserdu revenue exposure is concentrated in the ESR1-mutated, endocrine-resistant metastatic breast-cancer segment. The product’s value is tied to:

• the size of the ESR1-tested population;
• adoption of routine ESR1 mutation testing;
• use after CDK4/6 inhibitor therapy;
• duration of treatment;
• reimbursement and specialty-pharmacy access;
• competition from other oral estrogen receptor degraders.

Generic erosion would likely be gradual if the product has multiple strengths, method-of-use claims, and strong physician adoption. The most exposed revenue would come from the standard 345 mg tablet. The 86 mg tablet may be less attractive as a standalone generic product but remains important for dose management and portfolio completeness.

Key Takeaways

• Orserdu is an immediate-release oral tablet containing elacestrant hydrobromide in 86 mg and 345 mg strengths.
• Public labeling identifies conventional excipients, including lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate.
• The main formulation opportunity is reducing food-related exposure variability or improving administration convenience.
• A reference-matched ANDA is the most direct generic strategy. A food-independent or patient-friendly product would more likely require a 505(b)(2) application.
• Five-year NCE exclusivity began on January 27, 2023, making January 27, 2028 the key statutory date for routine ANDA approval, subject to patent and other regulatory barriers.
• Biosimilar competition is irrelevant because elacestrant is a small molecule.
• The strongest patent protection would combine active-ingredient, solid-form, formulation, manufacturing, and method-of-use claims.
• Excipient suppliers have commercial opportunities in direct compression, disintegration, coating, stability, process yield, and food-effect control.
• Manufacturing know-how may remain commercially important even where the final excipient list is public.
• Licensing value is highest for a formulation that produces a label-level clinical benefit, not merely a lower-cost tablet.

FAQs About Orserdu Excipient and Formulation Opportunities

Can a generic manufacturer use different excipients from Orserdu?

Yes. An ANDA applicant may use different excipients if the product satisfies applicable qualitative and quantitative requirements, demonstrates bioequivalence, and meets dissolution, stability, quality, and manufacturing standards.

Is Orserdu a good candidate for an amorphous solid-dispersion reformulation?

It may be a technically relevant candidate if solubility, dissolution, or food-related absorption limits performance. The commercial case depends on physical stability, dose loading, manufacturability, and whether the reformulation supports a meaningful regulatory or clinical advantage.

Could Orserdu be developed as an oral liquid?

A liquid or suspension could address swallowing difficulties, but it would require control of dose uniformity, chemical stability, precipitation, palatability, container compatibility, and preservative performance. It would likely require a 505(b)(2) pathway rather than a simple ANDA.

Does Orserdu have biosimilar competition?

No. Elacestrant is a synthetic small molecule. Potential competitors would use generic-drug or 505(b)(2) pathways, not the biosimilar pathway.

Why is the 86 mg Orserdu tablet commercially important?

The 86 mg strength supports dose reductions and toxicity management from the 345 mg regimen. It also increases portfolio complexity for generic manufacturers because a commercially credible copy may need to provide both strengths and maintain consistent formulation performance.

References

1. U.S. Food and Drug Administration. (2023a). Orserdu (elacestrant) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023b). Drugs@FDA: Orserdu application and regulatory information. FDA.

3. U.S. Food and Drug Administration. (2023c). FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA.

4. Radius Health, Inc. (2023). Annual report and regulatory disclosures concerning elacestrant and Orserdu. U.S. Securities and Exchange Commission.

5. Menarini Group. (2024). Corporate and commercial disclosures for Orserdu and oncology products. Menarini Group.